Methylphenidate "sandoz"

Methylphenidate, the active ingredient in Methylphenidate sandoz, is a central nervous system stimulant presented as an oral tablet for oral use. It is indicated for the management of attention deficit hyperactivity disorder and narcolepsy in children, adolescents, and adults.

GNH USA supplies Methylphenidate sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methylphenidate is a psychostimulant used in disorders that involve deficits in attention and wakefulness. - Attention deficit hyperactivity disorder (ADHD): improves concentration, reduces hyperactivity and impulsivity. - Narcolepsy: decreases excessive daytime sleepiness and reduces cataplexy episodes.

Methylphenidate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced hunger leading to weight loss. - Headache: mild to moderate cranial pain. - Stomach upset: nausea, abdominal discomfort. - Irritability: mood swings or increased agitation.

Serious or Rare Side Effects: - Cardiovascular events: chest pain, hypertension, arrhythmia. - Psychiatric symptoms: hallucinations, severe anxiety, mania. - Growth suppression: reduced height velocity in children. - Tics or worsening of pre‑existing tics. - Allergic reactions: rash, pruritus, angioedema.

Methylphenidate requires careful monitoring due to its stimulant properties and potential for misuse. - Cardiovascular assessment: evaluate blood pressure and heart rate before initiating therapy. - Psychiatric history: screen for anxiety, bipolar disorder, or psychosis. - Growth monitoring: track height and weight in pediatric patients regularly. - Substance abuse risk: avoid use in individuals with a history of drug dependence. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Methylphenidate can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: increased cardiovascular side effects. - Antihypertensive agents: may reduce blood pressure control.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may affect absorption. - Anticonvulsants (e.g., carbamazepine): may decrease plasma levels. - SSRIs and SNRIs: potential for additive serotonergic effects.